Bivalirudin in acute coronary syndromes

References

• Mortality GBD, Causes of Death C. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet (London, England). 2015;385(9963):117–171.
   PubMed Web of Science ®Google Scholar
• Abbate R, Cioni G, Ricci I, et al. Thrombosis and acute coronary syndrome. Thromb Res. 2012;129(3):235–240. doi: 10.1016/j.thromres.2011.12.026
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Galli M, Collet JP, et al. Antiplatelet therapy after percutaneous coronary intervention. EuroIntervention. 2022;17(17):e1371–e96. doi: 10.4244/EIJ-D-21-00904
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Rollini F, Franchi F. The quest for the optimal periprocedural antithrombotic treatment strategy in ACS patients undergoing PCI. J Am Coll Cardiol. 2018;71(11):1243–1245. doi: 10.1016/j.jacc.2018.01.040
   PubMed Web of Science ®Google Scholar
• Franchi F, Rollini F, Angiolillo DJ. Antithrombotic therapy for patients with STEMI undergoing primary PCI. Nat Rev Cardiol. 2017;14(6):361–379. doi: 10.1038/nrcardio.2017.18
   PubMed Web of Science ®Google Scholar
• Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87–165. doi: 10.1093/eurheartj/ehy394
   PubMed Web of Science ®Google Scholar
• Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177. doi: 10.1093/eurheartj/ehx393
   PubMed Web of Science ®Google Scholar
• Galli M, Andreotti F, D’Amario D, et al. Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2020;6(1):43–56. doi: 10.1093/ehjcvp/pvz031
   PubMed Web of Science ®Google Scholar
• Galli M, Porto I, Andreotti F, et al. Early anticoagulation in the current management of NSTE-ACS: evidence, guidelines, practice and perspectives. Int J Cardiol. 2019;275:39–45. doi: 10.1016/j.ijcard.2018.10.087
   PubMed Web of Science ®Google Scholar
• Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest. 2001;119(1 Suppl):108S–121S. doi: 10.1378/chest.119.1_suppl.108S
   PubMed Web of Science ®Google Scholar
• Galli M, Laborante R, Andreotti F, et al. Bleeding complications in patients undergoing percutaneous coronary intervention. Rev Cardiovasc Med. 2022;23(8):286. doi: 10.31083/j.rcm2308286
   Web of Science ®Google Scholar
• Galli M, Angiolillo DJ. De-escalation of antiplatelet therapy in acute coronary syndromes: why, how and when? Front Cardiovasc Med. 2022;9:975969. doi: 10.3389/fcvm.2022.975969
   PubMedGoogle Scholar
• Writing Committee M, Lawton JS, Tamis-Holland JE, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American college of cardiology/american heart association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2022;79(2):e21–e129. doi: 10.1016/j.jacc.2021.09.006
   PubMedGoogle Scholar
• Salter BS, Weiner MM, Trinh MA, et al. Heparin-induced thrombocytopenia: a comprehensive clinical review. J Am Coll Cardiol. 2016;67(21):2519–2532. doi: 10.1016/j.jacc.2016.02.073
   PubMed Web of Science ®Google Scholar
• Galli M, Angiolillo DJ. The evaluation and management of coagulopathies in the intensive therapy units. Eur Heart J Acute Cardiovasc Care. 2023;12(6):399–407. doi: 10.1093/ehjacc/zuad051
   PubMed Web of Science ®Google Scholar
• Maraganore JM, Chao B, Joseph ML, et al. Anticoagulant activity of synthetic hirudin peptides. J Biol Chem. 1989;264(15):8692–8698. doi: 10.1016/S0021-9258(18)81848-8
   PubMed Web of Science ®Google Scholar
• Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355(21):2203–2216. doi: 10.1056/NEJMoa062437
   PubMed Web of Science ®Google Scholar
• Kastrati A, Neumann FJ, Schulz S, et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med. 2011;365(21):1980–1989. doi: 10.1056/NEJMoa1109596
   PubMed Web of Science ®Google Scholar
• Laine M, Lemesle G, Dabry T, et al. Bivalirudin during percutaneous coronary intervention in acute coronary syndromes. Expert Opin Pharmacother. 2019;20(3):295–304. doi: 10.1080/14656566.2018.1551361
   PubMed Web of Science ®Google Scholar
• Gordon G, Rastegar H, Schumann R, et al. Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. J Cardiothorac Vasc Anesth. 2003;17(5):632–635. doi: 10.1016/S1053-0770(03)00210-6
   PubMed Web of Science ®Google Scholar
• Clayton SB, Acsell JR, AJ C, et al. Cardiopulmonary bypass with bivalirudin in type II heparin-induced thrombocytopenia. Ann Thorac Surg. 2004;78(6):2167–2169. doi: 10.1016/S0003-4975(03)01471-1
   PubMed Web of Science ®Google Scholar
• Gaigl Z, Pfeuffer P, Raith P, et al. Tolerance to intravenous heparin in patients with delayed-type hypersensitivity to heparins: a prospective study. Br J Haematol. 2005;128(3):389–392. doi: 10.1111/j.1365-2141.2004.05321.x
   PubMed Web of Science ®Google Scholar
• De Caterina R, Husted S, Wallentin L, et al. General mechanisms of coagulation and targets of anticoagulants (Section I). Position paper of the ESC Working group on thrombosis–task force on anticoagulants in Heart disease. Thromb Haemost. 2013;109(4):569–579. doi: 10.1160/TH12-10-0772
   PubMed Web of Science ®Google Scholar
• Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–1367. doi: 10.1093/eurheartj/ehaa575
   PubMed Web of Science ®Google Scholar
• Bikdeli B, Erlinge D, Valgimigli M, et al. Bivalirudin versus heparin during PCI in NSTEMI: individual patient data meta-analysis of large randomized trials. Circulation. 2023;148(16):1207–1219. doi: 10.1161/CIRCULATIONAHA.123.063946
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Frigoli E, Leonardi S, et al. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med. 2015;373(11):997–1009. doi: 10.1056/NEJMoa1507854
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Frigoli E, Leonardi S, et al. Bivalirudin or unfractionated heparin in acute coronary syndromes. 2015;373(11):997–1009. doi: 10.1056/NEJMoa1507854
   Google Scholar
• Gargiulo G, Carrara G, Frigoli E, et al. Post-procedural bivalirudin infusion at full or low regimen in patients with acute coronary Syndrome. J Am Coll Cardiol. 2019;73(7):758–774. doi: 10.1016/j.jacc.2018.12.023
   PubMed Web of Science ®Google Scholar
• Erlinge D, Omerovic E, Frobert O, et al. Bivalirudin versus heparin monotherapy in myocardial infarction. N Engl J Med. 2017;377(12):1132–1142. doi: 10.1056/NEJMoa1706443
   PubMed Web of Science ®Google Scholar
• Galli M, Gargiulo G, Benenati S, et al. Bivalirudin plus a high-dose infusion versus heparin in patients with acute coronary syndrome. Eur Heart J Cardiovasc Pharmacother;2023. doi: 10.1093/ehjcvp/pvad029
   Google Scholar
• Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358(21):2218–2230. doi: 10.1056/NEJMoa0708191
   PubMed Web of Science ®Google Scholar
• Ando G, Capodanno D. Radial access reduces mortality in patients with acute coronary syndromes: results from an updated trial sequential analysis of randomized trials. JACC Cardiovasc Interv. 2016;9(7):660–670. doi: 10.1016/j.jcin.2015.12.008
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–1057. doi: 10.1056/NEJMoa0904327
   PubMed Web of Science ®Google Scholar
• Saito S, Isshiki T, Kimura T, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circ J. 2014;78(7):1684–1692. doi: 10.1253/circj.CJ-13-1482
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015. doi: 10.1056/NEJMoa0706482
   PubMed Web of Science ®Google Scholar
• Steg PG, van ‘t Hof A, Hamm CW, et al. Bivalirudin started during emergency transport for primary PCI. N Engl J Med. 2013;369(23):2207–2217. doi: 10.1056/NEJMoa1311096
   PubMed Web of Science ®Google Scholar
• Clemmensen P, Wiberg S, Van’t Hof A, et al. Acute stent thrombosis after primary percutaneous coronary intervention: insights from the EUROMAX trial (European ambulance acute coronary Syndrome angiography). JACC Cardiovasc Interv. 2015;8(1 Pt B):214–220. doi: 10.1016/j.jcin.2014.11.002
   PubMed Web of Science ®Google Scholar
• Shahzad A, Kemp I, Mars C, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet (London, England). 2014;384(9957):1849–1858. doi: 10.1016/S0140-6736(14)60924-7
   PubMed Web of Science ®Google Scholar
• Schulz S, Richardt G, Laugwitz KL, et al. Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2014;35(34):2285–2294. doi: 10.1093/eurheartj/ehu182
   PubMed Web of Science ®Google Scholar
• Han Y, Guo J, Zheng Y, et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA. 2015;313(13):1336–1346. doi: 10.1001/jama.2015.2323
   PubMed Web of Science ®Google Scholar
• Li Y, Liang Z, Qin L, et al. Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial. Lancet (London, England). 2022;400(10366):1847–1857. doi: 10.1016/S0140-6736(22)01999-7
   PubMed Web of Science ®Google Scholar
• Fahrni G, Wolfrum M, De Maria GL, et al. Prolonged high-dose bivalirudin infusion reduces major bleeding without increasing stent thrombosis in patients undergoing primary percutaneous coronary intervention: novel insights from an updated meta-analysis. J Am Heart Assoc. 2016;5(7). doi: 10.1161/JAHA.116.003515
   PubMed Web of Science ®Google Scholar
• Galli M, Ortega-Paz L, Franchi F, et al. Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary intervention. Pharmacogenomics. 2022;23(13):723–737. doi: 10.2217/pgs-2022-0057
   PubMed Web of Science ®Google Scholar
• Shah R, Rogers KC, Matin K, et al. An updated comprehensive meta-analysis of bivalirudin vs heparin use in primary percutaneous coronary intervention. Am Heart J. 2016;171(1):14–24. doi: 10.1016/j.ahj.2015.10.006
   PubMed Web of Science ®Google Scholar
• Shah R, Rogers KC, Ahmed AJ, et al. Effect of post-primary percutaneous coronary intervention bivalirudin infusion on acute stent thrombosis: Meta-analysis of randomized controlled trials. JACC Cardiovasc Interv. 2016;9(13):1313–1320. doi: 10.1016/j.jcin.2016.03.031
   PubMed Web of Science ®Google Scholar
• Shah R, Latham SB, Porta JM, et al. Bivalirudin with a post-procedure infusion versus heparin monotherapy for the prevention of stent thrombosis. Catheter Cardiovasc Interv Off J Soc Card Angiography Interv. 2019;94(2):210–215. doi: 10.1002/ccd.28065
   PubMed Web of Science ®Google Scholar
• Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2023;44(38):3720–3826. doi: 10.1093/eurheartj/ehad191
   PubMed Web of Science ®Google Scholar
• Waksman R, Wolfram RM, Torguson RL, et al. Switching from enoxaparin to bivalirudin in patients with acute coronary syndromes without ST-segment elevation who undergo percutaneous coronary intervention. Results from SWITCH–a multicenter clinical trial. J Invasive Cardiol. 2006;18(8):370–375.
   PubMedGoogle Scholar